Literature DB >> 20721461

Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals.

Ana Lúcia Farias de Azevedo Salgado1, Luciana de Carvalho, Ana Claudia Oliveira, Virgínia Nascimento dos Santos, Jose Gilberto Vieira, Edison Roberto Parise.   

Abstract

CONTEXT: Due to its good correlation to glycemic clamp, HOMA-IR has been widely utilized as insulin resistance index in clinical and epidemiological studies involving non-alcoholic fatty liver disease carriers. However, values used for this parameter have shown large variability.
OBJECTIVE: To identify the HOMA-IR cut value that best distinguishes non-diabetic non-alcoholic fatty liver disease patients from a control group.
METHODS: One hundred sixteen non-alcoholic fatty liver disease patients were studied, diagnosed by clinical, biochemical, and liver image or biopsy criteria, and 88 healthy individuals, without any liver disease and testing for oral glucose tolerance within normality. These groups did not differ in age and gender. All were submitted to oral glucose tolerance test and blood samples were collected for glucose and insulin measurements by immunofluorometric method. HOMA-IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.
RESULTS: NAFLD patients showed higher insulin, glycemia, and HOMA-IR values than control group, even when excluding glucose intolerant and diabetes mellitus patients by their glycemic curves. HOMA-IR 75th percentile for control group was 1.78 and the best area under the curve index was obtained for HOMA-IR values of 2.0 [AUC= 0.840 (0.781-0.899 CI 95%), sensitivity (Se): 85%, specificity (Sp): 83%] while value 2.5 showed best specificity without important loss in sensitivity [AUC=0,831 (0.773-0.888) Se = 72%, Sp = 94%].
CONCLUSION: HOMA-IR values above or equal to 2.0 or 2.5 show enhanced diagnostic value in distinguishing non-alcoholic fatty liver disease carriers from control group individuals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20721461     DOI: 10.1590/s0004-28032010000200009

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  74 in total

1.  Insulin activation of plasma nonesterified fatty acid uptake in metabolic syndrome.

Authors:  Maria A Ramos-Roman; Smadar A Lapidot; Robert D Phair; Elizabeth J Parks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

2.  Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.

Authors:  Elina Isokuortti; You Zhou; Markku Peltonen; Elisabetta Bugianesi; Karine Clement; Dominique Bonnefont-Rousselot; Jean-Marc Lacorte; Amalia Gastaldelli; Detlef Schuppan; Jörn M Schattenberg; Antti Hakkarainen; Nina Lundbom; Pekka Jousilahti; Satu Männistö; Sirkka Keinänen-Kiukaanniemi; Juha Saltevo; Quentin M Anstee; Hannele Yki-Järvinen
Journal:  Diabetologia       Date:  2017-06-29       Impact factor: 10.122

Review 3.  Predictive factors associated with hepatitis C antiviral therapy response.

Authors:  Lourianne Nascimento Cavalcante; André Castro Lyra
Journal:  World J Hepatol       Date:  2015-06-28

4.  Pu'erh tea extract-mediated protection against hepatosteatosis and insulin resistance in mice with diet-induced obesity is associated with the induction of de novo lipogenesis in visceral adipose tissue.

Authors:  Xianbin Cai; Shuhei Hayashi; Chongye Fang; Shumei Hao; Xuanjun Wang; Shuhei Nishiguchi; Hiroko Tsutsui; Jun Sheng
Journal:  J Gastroenterol       Date:  2017-03-31       Impact factor: 7.527

5.  Potential influence of the phthalates on normal liver function and cardiometabolic risk in males.

Authors:  Nataša Milošević; Nataša Milić; Dragana Živanović Bosić; Ivana Bajkin; Ivanka Perčić; Ludovico Abenavoli; Milica Medić Stojanoska
Journal:  Environ Monit Assess       Date:  2017-12-13       Impact factor: 2.513

Review 6.  Weight control and prevention of metabolic syndrome by green tea.

Authors:  Sudathip Sae-tan; Kimberly A Grove; Joshua D Lambert
Journal:  Pharmacol Res       Date:  2010-12-28       Impact factor: 7.658

7.  Could phthalates exposure contribute to the development of metabolic syndrome and liver disease in humans?

Authors:  Nataša Milošević; Maja Milanović; Jan Sudji; Dragana Bosić Živanović; Stefan Stojanoski; Bojan Vuković; Nataša Milić; Milica Medić Stojanoska
Journal:  Environ Sci Pollut Res Int       Date:  2019-12-06       Impact factor: 4.223

8.  Genetic ancestry analysis in non-alcoholic fatty liver disease patients from Brazil and Portugal.

Authors:  Lourianne Nascimento Cavalcante; Jose Tadeu Stefano; Mariana V Machado; Daniel F Mazo; Fabiola Rabelo; Kiyoko Abe Sandes; Flair José Carrilho; Helena Cortez-Pinto; Andre Castro Lyra; Claudia P de Oliveira
Journal:  World J Hepatol       Date:  2015-06-08

9.  Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis.

Authors:  Yang Yao; Xiangxia Miao; Donglie Zhu; Dongmin Li; Ying Zhang; Chengyan Song; Kaige Liu
Journal:  Endocrine       Date:  2019-06-26       Impact factor: 3.633

10.  ASSOCIATION OF IRS1 GLY971ARG GENE POLYMORPHISM WITH INSULIN RESISTANCE IN IRANIAN NEWLY DIAGNOSED DIABETIC ADULTS.

Authors:  H Shakeri; A Khoshi; M Kaffash Bajestani; A Farahi; M S Javadzadeh; Z Hosseini; R Mohammadi
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jul-Sep       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.